Atlas Trials

Cluster of Differentiation Antigen 19/22(CD19/22) CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma

Clinical trial NCT03287817 · TERMINATED

Trial details

NCT number
NCT03287817
Sponsor
Autolus Limited
Status
TERMINATED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Start date
2017-09-05
Primary completion
2023-10-19
Enrollment
52

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.